Valuation: GI Dynamics, Inc.

Market Cap 440K 395K 364K 329K 616K 41.95M 626K 4.34M 1.73M 21.95M 1.65M 1.62M 69.53M P/E 2019
-1.12x
P/E 2020 -0.03x
Enterprise Value 3.28M 2.94M 2.71M 2.45M 4.59M 312M 4.66M 32.33M 12.9M 163M 12.31M 12.05M 518M EV / Sales 2019
-
EV / Sales 2020 -
Free-Float
-
Yield 2019 *
-
Yield 2020 -
Manager TitleAgeSince
Chief Executive Officer - 05/08/2025
Director of Finance/CFO 57 01/08/2025
Chief Tech/Sci/R&D Officer - 01/04/2023
Director TitleAgeSince
Director/Board Member - 20/10/2020
Director/Board Member - -
Director/Board Member 69 01/10/2023
Date Insider Type Main position Quantity % Market Cap. Importance
28/01/21 Free

Chairman

1,384,483 0.4875%
28/01/21 Free

Chief Executive Officer

11,075,869 3.8998%

Financials

2019 2020
Net sales - -
Net income -17.33M -15.53M -14.32M -12.96M -24.24M -1.65B -24.63M -171M -68.17M -864M -65.05M -63.66M -2.74B -11.14M -9.97M -9.2M -8.33M -15.57M -1.06B -15.82M -110M -43.8M -555M -41.79M -40.9M -1.76B
Net Debt 2.89M 2.59M 2.39M 2.16M 4.04M 275M 4.1M 28.46M 11.35M 144M 10.83M 10.6M 456M 2.84M 2.54M 2.35M 2.12M 3.97M 270M 4.03M 27.99M 11.17M 141M 10.65M 10.43M 448M
Logo GI Dynamics, Inc.
GI Dynamics, Inc. is a medical device company. The Company designs and applies device and disease management solutions for the treatment of metabolic disease. The Company designs, develops, manufactures and markets medical devices for non-surgical approaches to treat type II diabetes and obesity. The Company's product, EndoBarrier, is an endoscopically-delivered device therapy, which is approved for the treatment of obese type II diabetes with body mass index (BMI) greater than or equal to 30 kilogram/square meter (kg/m2), or obese patients with BMI greater than or equal to 30 kg/m2 with greater than or equal to one comorbidities, or obese patients with BMI over 35 kg/m2. EndoBarrier is an incision-free, non-anatomy altering solution designed to specifically mimic the duodenal-jejunal exclusion created by gastric bypass surgery.
Employees
-
Sector
-
  1. Stock Market
  2. Stocks
  3. GIDYL Stock